    Christopher Haqq | Atara Biotherapeutics, Inc. | ZoomInfo.com










 













 




Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Christopher M. Haqq M.D., Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 10:53 PM ET
Biotechnology

Company Overview of Atara Biotherapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Christopher M. Haqq M.D., Ph.D.Executive VP of R&D and Chief Scientific Officer, Atara Biotherapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.51$3,298,022As of Fiscal Year 2016
Background

		Dr. Christopher M. Haqq, also known as Chris, M.D., Ph.D. has been Chief Scientific Officer and Executive Vice President of R&D at Atara Biotherapeutics, Inc. since September 2012 and served as its Chief Medical Officer since September 2012. Dr. Haqq served as Vice President of Clinical Research & Development of Cougar Biotechnology, Inc. Dr. Haqq has over 8 years of clinical and translational research experience in oncology. Dr. Haqq joined Cougar Biotechnology, Inc. ... in March 2007 and served as its Senior Director of Clinical Research and Development since May 2007. From 2005 to March 2007, Dr. Haqq was employed by Amgen Inc., where he led the Early Development Oncology Group. In that role, he successfully recruited and managed a team of M.D. and M.D./Ph.D. clinical scientists for Amgen's Phase I and Phase II oncology product candidates. He served as an attending Urologic Oncologist at the UCSF Prostate Cancer Center. He was a Faculty Member in the Departments of Medicine and Urology at the University of California, San Francisco (UCSF). He received his M.D. and Ph.D. degrees in 1996 from Harvard Medical School. Dr. Haqq completed his Residency in Internal Medicine and Fellowships in Medical Oncology and Molecular Medicine at UCSF.Read Full Background




Corporate Headquarters
611 Gateway BoulevardSouth San Francisco, California 94080United StatesPhone: 650-278-8930Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
BS Stanford UniversityPhD 1996Harvard Medical SchoolMD 1996Harvard Medical School
Other Affiliations
Stanford UniversityHarvard Medical SchoolCougar Biotechnology, Inc.


Annual Compensation
Salary$416,000Bonus$154,752Total Annual Compensation$570,752
Stocks Options
Restricted Stock Awards$2,723,502All Other Compensation$3,768Exercisable Options$65,638Unexercisable Options$100,695Total Number of Options$166,333
Total Compensation
Total Annual Cash Compensation$574,520Total Short Term Compensation$570,752Other Long Term Compensation$2,727,270Total Calculated Compensation$3,298,022




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Atara Biotherapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft












Christopher Michael Haqq - Newbury Park, CA | Intelius



























Sign In



We found Christopher Michael Haqq in Newbury Park, CA


Christopher Michael Haqq

                                                                           Intelius found that Christopher Michael Haqq  is  a male between 50 and 60 years old from Newbury Park, CA.  We have connected them to
                11 addresses,
                7 phones,
                and 2 relatives or associates.
         





Also Known As

Chris  Haqq
Christopher  Happ


Get Report Now

Age

Christopher Michael Haqq is in his 50s

Christopher Has Lived In

Newbury Park, CA
Cambridge, MA
Hialeah, FL

Christopher's Relatives

Lynn Phung
Bao Phung







Christopher Michael Haqq



Zodiac SignSagittarius



GenderMale



Professional Status
Materials Program Manager at Intel Corporation



Get Report Now










Want to know more about Christopher? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Christopher, or use our people search engine to find others.
Get Background Check on Christopher Michael Haqq
Get a Criminal Check on Christopher Michael Haqq
Get a Public Record Report on Christopher Michael Haqq
Get a People Search Report on Christopher Michael Haqq


Christopher Michael Haqq's Contact Information
Known Cities Lived In
Find out where Christopher Michael Haqq has lived as well as Christopher Michael Haqq's phone numbers and email addresses.




Christopher Michael Haqq Has Lived in 3 States
California Address for Christopher Michael Haqq


568 H******** A** 

Newbury Park, CA


Has Lived In

Newbury Park, CA
Cambridge, MA


Get Full Address Report










Phone Numbers Associated with Christopher Michael Haqq

(805) ***-**** - Newbury Park, CA 
(310) ***-**** - Los Angeles, CA 
(408) ***-**** - Santa Clara, CA 


Get Full Phone Report



Email Addresses Associated with Christopher Michael Haqq

c***q@***.com
c*************q@***.net
c***q@***.edu


Get Email Report




Christopher Michael Haqq's Education Information
Known Schools Attended
Learn about Christopher Michael Haqq's academic history.  Find out which schools Christopher Michael Haqq attended, the dates attended as well as the degrees Christopher Michael Haqq received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Christopher Michael Haqq Has Attended 2 Schools
Harvard Medical School 1987 – 1996               Christopher Michael Haqq has a MD PhD in Medicine, Genetics               
Stanford University               1984 – 1987               Christopher Michael Haqq has a Bs in Biological Sciences               


Christopher Michael Haqq's Professional Information
Information regarding Christopher Michael Haqq's professional history.  Find out previous places Christopher Michael Haqq has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Christopher Michael Haqq Has Worked at 8 Places
Company: Intel Corporation
               Title: Materials Program Manager
Company: Atara Biotherapeutics, Inc.
               Title: Chief Medical Officer
Christopher Michael Haqq's Experience
Title: Materials Program Manager
               Company: Intel Corporation
Job Details
               Company Size: $1 bil and above - Employee Range: 100,000 and above. Intel (NASDAQ: INTC) makes the most amazing experiences of the future possible. Intel's innovations expand the reach and power of computing in personal devices and enterprise servers, the Cloud, make the Internet of Things smart and connected, and help ensure the security of our digital lives. The work of the company's more than 100,000 employees transforms businesses, propels new discoveries and improves human experiences.
Title: Chief Medical Officer
               Company: Atara Biotherapeutics, Inc.
Job Details
               Company Size: $5 mil to less than $10 mil - Employee Range: Less than 25. Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation. Atara Bios programs include molecularly targeted product candidates and T-cell product candidates. Molecularly targeted product candidates include PINTA 745, STM 434 and ATA 842. These product candidates target myostatin and activin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications. T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL.
Additional Professional Information on Christopher Michael Haqq

 See Christopher Michael Haqq's LinkedIn Profile



Christopher Michael Haqq's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Christopher Michael Haqq


Christopher Michael Haqq's known Social Networks And Potential Email Matches

Find all of Christopher Michael Haqq's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Christopher Haqq
Username Matches

                  ChristopherHaqq
                  HaqqChristopher
                  Christopher.Haqq
                  Haqq.Christopher
                  Christopher_Haqq
                  Haqq_Christopher
                  Christopher-Haqq
                  Haqq-Christopher
                  CHaqq
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
C Haqq







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











﻿







Christopher Haqq, Atara Biotherapeutics Inc (NASDAQ:ATRA)’s insider Unloaded 5,000 Shares – Octafinance
























































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Christopher Haqq, Atara Biotherapeutics Inc (NASDAQ:ATRA)’s insider Unloaded 5,000 Shares


09/01/2015  by OctaStaff 
			in Insider News 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Christopher Haqq, Atara Biotherapeutics Inc (NASDAQ:ATRA)’s insider Unloaded 5,000 Shares and is was published by Octafinance.com at http://www.octafinance.com/christopher-haqq-atara-biotherapeutics-inc-nasdaqatras-insider-unloaded-5000-shares/182820/.CaptchaSubmit
Christopher Haqq Insider Sell Transaction
 Stock trade amounting to exactly $209,961 U.S Dollars was published in a public form submitted to the Security and Exchange Commission on 01/09/2015. According to which, Christopher Haqq, the Chief Medical Officer of Atara Biotherapeutics Inc (NASDAQ:ATRA)  15.00 -0.20 -1.32% also an insider of the company had unloaded precisely 5,000 shares – ( at $42.0 for share ). This is not his first insider trade, in the last 30 days, he unloaded another 4,104 shares worth $212,207 USD. Christopher Haqq now owns 260,890 shares or 0.95% of the Company’s total market cap. 
Atara Biotherapeutics Inc Stock Rating, Sentiment and Fundamentals
 Moreover, the analysts of the corporation’s financials indicated a forecast for earnings-per-share of $-2.11, according to which Atara Biotherapeutics Inc’s Price/Earnings ratio would be NaN. 






Rating & SentimentPsychSignal Social:SELLAnalysts Rating:BUYHedge Funds Sentiment:BUY




Stock FundamentalsEarnings + FCF Trend:SELLSector/Industry Macro:BULLISHValuation Models:-


 


Technical AnalysisST Trend:DOWNMT Trend:NEUTRALLT Trend:UP




OctaFinance Rating*:SELL


* Read How Our Stock Ratings System Works








 The stock price of Atara Biotherapeutics Inc’s has decreased 28.01% in just the last 50 days, showing a strong and smooth downtrend. Our trend model, coupled with Christopher’s transaction, certainly serves to classify this stock as a SELL. 
Price Chart of Atara Biotherapeutics NASDAQ:ATRA Stock
 
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
 As famous stock traders including Peter Lynch stated, best money is made through a combination of fundamental & technical analysis.
Hedge Funds Ownership
 Recently released 13F public data filings reveal 38 institutional investors own shares of Atara Biotherapeutics Inc. In Q4 2014, the firm had 46.90% institutional ownership. That is a low interest.

 Ecor1 Capital Llc is the most bullish institutional investor on Atara Biotherapeutics Inc, with ownership of 385,124 shares as of Q4 2014 for 5.13% of the fund’s portfolio. Seth Klarman’s Baupost Group Llc Ma is another bullish asset manager having 2.50 million shares of the company or 1.16% of their stocks portfolio. The stock is also 0.2% of the fund’s AUM. Further The New York-based fund Bridger Management Llc have 0.41% of their stock portfolio invested in the company’s market cap for 243,450 shares. The California-based fund Redmile Group Llc disclosed it had purchased a stake worth 0.77% of the fund’s stock portfolio in Atara Biotherapeutics Inc. The New York-based fund Visium Asset Management Lp is also very upbeat about the public company, owning 690,148 shares or 0.26% of their stock portfolio.
Atara Biotherapeutics NASDAQ:ATRA Company Profile
Atara Biotherapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate, STM 434, which is in a Phase I clinical study, is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842, a humanized antibody targeting myostatin; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-ActR2A/2B monoclonal antibody; STM 217, a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434, and ActR2B5, a soluble ActR2B receptor that can be fused to an IgG Fc receptor.
Company Website: Atara Biotherapeutics
 Atara Biotherapeutics Inc has 18 employees. Currently its market worth is: $1.11 billion and it has 27.39 million outstanding shares. Today it has 46.53% shareholders and the institutional ownership stands at 46.53%. Atara Biotherapeutics Inc was filled in Delaware on 2012-08-22. The stock closed at $39.02 yesterday and it had average 2 days volume of 87058 shares. It is up from the 30 days average shares volume of 70960. Atara Biotherapeutics Inc has a 52w low of $9.66 and a one year high of $199999.99. The stock price is above the 200 days SMA. Atara Biotherapeutics Inc last issued its quarterly earnings stats on 08/06/2015. The company reported -0.43 EPS for the quarter, missing the consensus estimate of -0.42 by 0.01. The company had a revenue of for 6/30/2015 and for 3/31/2015. Therefore, the revenue was down.
* Transaction pursuant to Rule 10b5-1 Plan adopted March 11 – 2015.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.85 to $41.84. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.89 to $42.37. The reporting person will provide to the issuer – any security holder of the issuer – or the SEC staff – upon request – information regarding the number of shares sold at each price within the range.
* The shares are held by the Chris Haqq 2014 GRAT – of which the Reporting Person is trustee.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.







 
Tagged: Atara Biotherapeutics - (NASDAQ:ATRA)Christopher Haqq



What after Kevin Weil’s Insider Sale of Twitter Inc (NYSE:TWTR) Stock? Chubb Corp (NYSE:CB) Rating Decreased at Zacks to “hold” 



 





Free Email Newsletter
    Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:







Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?



















 






Christopher Haqq, Chief Medical Officer, Atara Biotherapeutics


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Christopher Haqq



Chief Medical Officer
at
Atara Biotherapeutics


Location: Greater Los Angeles Area





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Christopher Haqq



Chief Medical Officer
at
Atara Biotherapeutics


Location: Greater Los Angeles Area




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Dr. Christopher Haqq joined Atara Biotherapeutics as Chief Medical Officer in September 2012. He brings 20 years of clinical, academic and drug development experience from biopharma companies large and small. He was recently Vice President for Clinical Research and Development at Cougar Biotechnology and Johnson & Johnston’s Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early development studies of the anti-insulin like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Chris has worked closely with the European Medicines Agency, the U.S. Food and Drug Administration and other global regulatory agencies–filing IND applications, new drug applications, special protocol assessments and their international equivalents. Earlier in his career, Chris practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Chris completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in Medical Oncology and Internal Medicine. Chris is an inventor of three patents and an author of nearly 50 medical publications. In his free time, he enjoys astronomy and photography.



5

Companies in Career





N/A

Related Markets





4

Colleagues





N/A

Related Investments








Alias
N/A



Industry
Pharmaceuticals




Tags
Clinical Development, Clinical Trials, Cancer




Topics of Influence












N/A







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Christopher HaqqCareer (5)






2012




Atara Biotherapeutics



Chief Medical Officer







Sep-2011 to Aug-2012




Genomic Systems



CEO







Mar-2007 to Sep-2011




Ortho Biotech Oncology Research and Development, A Unit of Cougar Biotechnology



Medical Oncologist







2005 to 2007




Amgen



Med Director







2001 to 2005




UCSF



Assistant Adjunct Professor of Medicine








Competencies










 Edit
View all 



Christopher HaqqEducation (2)






1996



Harvard Medical School


Medicine, Genetics






1987



Stanford University


Biological Sciences









 Edit



Christopher HaqqAchievements and Recognitions





Add Milestone


No milestones has been recorded for Christopher Haqq






 Edit



Christopher HaqqLinks





Add Link


No links has been recorded for Christopher Haqq









Christopher HaqqInvestments/Acquisitions





No investments has been recorded for Christopher Haqq









Christopher HaqqInvestments Representing Others





No investment reps has been recorded for Christopher Haqq








Christopher HaqqRelated People








Colleagues at Atara Biotherapeutics







Joe Newell

Executive Vice President and Chief Technical Operations Officer
Apr-2017









David Carmel

Head of Immunotherapy
Mar-2015









Derrell Porter

Senior Vice President and Global Commercial Head
Jul-2014









Gad Soffer

Chief Operating Officer
Mar-2013








View all 
Peers (27)







Phil Febbo

Chief Medical Officer of Genomic Health









Shashidhar Kori

Chief Medical Officer of Autonomic Technologies









Vincent Miller

Chief Medical Officer of Foundation Medicine









Neil M. Barth

Chief Medical Officer of Veracyte









Jeff Dobro

Chief Medical Officer of RedBrick Health









Henry DePhillips

Chief Medical Officer of Teladoc












View all 



Christopher HaqqRecommended Market Profiles (2)








Life Sciences (Kleiner Perkins Caufield & Byers)

10,000 or More employees
58 companies








Healthcare Corporate Venture Deals

2,500 - 5,000 employees
56 companies


















